In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Blueprint signs on its first Big Pharma partner Roche in immuno-oncology deal; terms amended

Executive Summary

Roche received options to license exclusive worldwide discovery, development, and commercialization rights to up to five of Blueprint Medicines Corp.'s small-molecule immunokinase inhibitors in immuno-oncology. The companies may create monotherapies or combinations with Roche's existing drugs or immunotherapies from other companies.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Immuno-Oncology
    • Drug Discovery Tools
      • Bioinformatics
      • Molecular Diversity
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register